The Next Frontier of Medicines for Cardioendocrine Diseases. Backed by Third Rock Ventures.
About the role
Reporting to the Chief Technical Officer, the Vice President, Bioprocess and Analytical Development will provide strategic and operational leadership across Marea's core Technical Development functions — Upstream Process Development, Downstream Process Development, and Analytical Development — through late-stage clinical development. Found on 1752vc Careers, the job board for startup and VC roles.
What they're looking for
- Provide strategic and operational leadership across the Upstream Process Development, Downstream Process Development, and Analytical Development functions
- Working with CDMO and external partners, ensure delivery of all work packages covering process, analytical development, tech transfer, scale up, technical content for global regulatory submissions
- Lead, mentor, and develop the function heads and teams responsible for each of these areas
- Develop and execute an integrated technical development strategy that is synchronized with the cross functional project team's plans and translated into executable SOWs with external partners
- Lead technical development from IND-enabling stages through late-stage clinical development
- Provide strategic input to portfolio planning, development timelines, and investment decisions
More about this role
Marea Therapeutics is a clinical-stage biotechnology company based in South San Francisco with a growing pipeline of first-in-class therapies to address genetically validated cardioendocrine disease targets. Our therapies have the potential to serve as transformative treatment options for significant patient populations living with cardioendocrine diseases.
The company’s lead program, MAR001, is being developed for the treatment of severe hypertriglyceridemia (sHTG), a condition characterized by very high triglyceride levels and elevated risk of acute pancreatitis. Preclinical models with MAR001 demonstrated reduction in triglycerides, remnant cholesterol and ectopic fat, and improved insulin sensitivity. MAR001 has demonstrated strong and a differentiated profile in patients and is approaching Phase 3 development. Our second clinical asset, MAR002, is a monoclonal antibody targeting excess growth hormone produced by the pituitary gland in the rare hormonal disorder, acromegaly. MAR002 has potential to become best-in-disease and is quickly progressing into Phase 2/3 clinical development. We also have a third asset that is swiftly advancing through research discovery, with DC...
Browse similar: Startup jobs · San Francisco Bay Area